Paragon Capital Management Acquires 6,686 Shares in Biogen

The investment firm adds to its position in the biotech company

Apr. 13, 2026 at 10:52am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate financial machinery and equipment, conveying a sense of institutional power and wealth without using literal currency or charts.An institutional investor's increased stake in a major biotech company signals confidence in the sector's future.San Diego Today

Paragon Capital Management Inc. has acquired a new position in Biogen Inc. (NASDAQ:BIIB), purchasing 6,686 shares of the biotechnology company's stock in the fourth quarter. The shares were valued at approximately $1,177,000.

Why it matters

This transaction represents an institutional investor's increased confidence in Biogen's outlook and potential future performance. Institutional ownership can be an important indicator of a stock's overall strength and future prospects.

The details

According to a recent SEC filing, Paragon Capital Management Inc. bought 6,686 shares of Biogen stock in the fourth quarter. The purchase was part of the firm's broader investment strategy and portfolio management for its clients.

  • Paragon Capital Management acquired the Biogen shares in the fourth quarter of 2026.

The players

Paragon Capital Management Inc.

An investment management firm that provides portfolio management services to individual and institutional clients.

Biogen Inc.

A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the continued institutional interest in Biogen's stock and the company's standing as a leading player in the biotechnology industry. As Biogen navigates its product pipeline and market dynamics, investors will likely continue to monitor the company's performance and any changes in institutional ownership.